How has been the historical performance of Vanta Bioscience?

Answer:The historical performance of Vanta Bioscience shows a fluctuating trend in net sales and profitability over the years.

Breakdown:
In the fiscal year ending March 2024, Vanta Bioscience reported net sales of 9.72 Cr, an increase from 6.28 Cr in March 2023, but a slight decline from 9.69 Cr in March 2022. The total operating income mirrored this trend, reaching 9.72 Cr in March 2024. The company's total expenditure, excluding depreciation, was 8.41 Cr, a decrease from 8.67 Cr in the previous year. This resulted in an operating profit (PBDIT) of 1.42 Cr for March 2024, recovering from a loss of 1.70 Cr in March 2023. However, the company faced significant challenges, as it reported a profit before tax of -2.54 Cr and a net profit of -2.32 Cr in March 2024, although these figures represented improvements from the previous year's losses of -6.30 Cr and -6.48 Cr, respectively. The earnings per share (EPS) for March 2024 was -3.68, an improvement from -10.27 in March 2023. The operating profit margin for March 2024 was 13.48%, contrasting sharply with the -38.06% margin of the previous year, indicating a recovery in operational efficiency. Overall, while Vanta Bioscience has shown some signs of recovery in sales and operating profit, it continues to grapple with net losses.